Patients with hematologic malignancies face significantly higher short- and long-term risk for cardiovascular disease vs the general public.

(Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies ...

Medically integrated dispensing improves affordability, adherence, and toxicity management via embedded pharmacy teams, ...

In this free webinar, gain insight into new changes in molecular reclassification of hematologic malignancies and their effects in precision medicine. Attendees will learn about the use of molecular ...

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...

The MarketWatch News Department was not involved in the creation of this content.-- The agreement aims to expand access to the therapy in Brazil; -- The Technology is for patients ...

BUFFALO, N.Y. — There is new research happening at Roswell Park Comprehensive Cancer Center to see if CAR T-cell therapy that ...

Study finds sickle cell disease bias in clinical notes is linked more to opioid use than race or chronic pain in healthcare ...

Kartal Belediyesi, 14-20 Nisan Şehitler Haftası dolayısıyla düzenlediği özel bir programla aziz şehitleri rahmet ve minnetle andı. Şehit kabristanlığı ziyaretiyle başlayan anma etkinlikleri, gün boyu ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Predicta ...

Thirteen years after a lifesaving vaccine emerged, this illness once again threatens kids.